The updated 13-year NordICC data showed that colonoscopy screening reduced colorectal cancer incidence by about 30%, strengthening the benefit seen in the original 10-year analysis. However, the trial still did not demonstrate a statistically significant reduction in CRC mortality. Experts emphasized that the findings are heavily influenced by participation rates—only 42% of invited individuals actually underwent colonoscopy. The study reinforces that colonoscopy can be effective at reducing cancer incidence when completed, while also highlighting how improved modern cancer therapies may make mortality benefits harder to detect in screening trials.
Author: Abhay Panchal
Inflammatory bowel disease (IBD) presents unique challenges for older adults, particularly those in Medicare Advantage (MA) plans. In this population, multiple comorbidities and fragmented care pathways exacerbate disease burden and contribute to poorer outcomes. Traditional models often fail to provide proactive monitoring to prevent symptom escalation, Emergency Department use, and declining quality of life. Technology-enabled care coordination offers a promising approach to address these gaps. SonarMD’s program includes monthly patient-reported check-ins, alert thresholds, coordinator outreach, escalation to GI-directed care (earlier appointments, medication optimization, labs), and lifestyle support. We hypothesize that improved outcomes are associated with earlier intervention triggered by remote…
ECU Health has become the first institution in North Carolina to perform colorectal surgeries using the da Vinci SP system. The new robotic platform allows surgeons to perform complex colorectal procedures through a single small incision rather than multiple entry points used in traditional minimally invasive surgery. According to ECU Health, the system provides improved visualization and access to difficult anatomical angles, potentially allowing more precise treatment while preserving healthy tissue. The technology will be used across a broad range of colorectal conditions, including colon and rectal cancer resections, inflammatory bowel disease, diverticulitis, colectomies, rectal prolapse repair, and select benign…
A conversation between Meredith Hirsh and Anna Sobkiv (J.P. Morgan) explores how private equity is rapidly shaping physician practices—driving growth, acquisitions, and succession planning. The discussion highlights why investor interest is accelerating, which specialties are attracting capital, and what these deals mean for ownership, autonomy, and long-term sustainability of independent medicine. The signal: Private equity is no longer optional—it’s becoming a defining force in how physician practices grow, transition, and remain viable.
A recent JAMA viewpoint reframes the AI debate in medicine: the real disruption isn’t that AI is becoming more human—it’s that medicine has become less human over time. Despite headlines suggesting AI is surpassing physicians in empathy, the reality is more uncomfortable. Clinicians haven’t been outperformed at the bedside—they’ve been pulled away from it. Over decades, administrative layers—documentation, billing, prior authorization, and EHR work—have gradually displaced physicians from direct patient care, leaving less time for the human elements of medicine. In some settings, physicians now spend nearly twice as much time on desk work as with patients.
A new report from the American Medical Association shows physician burnout is gradually declining, with gains in job satisfaction and retention. But the bigger shift is structural: burnout is becoming highly specialty-specific, not universal. Gastroenterology lands squarely in the middle of this spectrum—at ~43.5% burnout—below peak-stress fields like emergency medicine, but still firmly in the high operational burden tier alongside cardiology and general surgery. This positioning matters. GI isn’t in crisis, but it’s also far from insulated. The drivers remain consistent across specialties: EHR friction, staffing shortages, and administrative overload. In GI, these are amplified by a unique combination of…
A key shift is emerging in physician practice strategy: independence is no longer about staying small—it’s about getting big enough to survive. Rising administrative complexity, staffing costs, and payer pressure are pushing smaller practices toward a structural disadvantage. The reality is stark—groups below ~40–50 providers often lack the infrastructure (leadership, contracting leverage, data systems) needed to operate sustainably, forcing them to consider mergers, partnerships, or external capital. At the same time, many physicians misunderstand what their practice is actually worth. Valuation isn’t based on total income—it’s based on “replaceable cash flow,” typically ~30% of physician earnings, meaning selling a practice…
GLP-1’s drugs continue to expand horizons in gastroenterology, bariatrics, diabetes and chronic disease care — but the scale of the drugs’ adoption could be creating new areas of risk management for physicians, according to a report published Risk & Insurance April 29.The first wave of concern relates to the proliferation of compounded medications and counterfeit products, according to the report. The FDA has raised concerns about unauthorized and improperly compounded GLP-1 formulations that may contain incorrect dosages or ingreidnets.
A study published in Clinical Gastroenterology and Hepatology highlights findings from the first-ever in-human trial using a special real-time artificial intelligence system to diagnose cancer in the digestive system. Led by Neil Marya, MD, assistant professor of medicine, director of the Program in Digital Medicine, and director of the Digital Medicine Fellowship at UMass Chan Medical School, the SMART-AI trial showed that using AI was better at diagnosing cholangiocarcinoma, or bile duct cancer, than a biopsy.
An investigational procedure—duodenal mucosal resurfacing (DMR)—is emerging as a potential solution to one of the biggest challenges in obesity care: what happens after GLP-1s are stopped. In a randomized, sham-controlled trial, patients who discontinued GLP-1 therapy typically regained weight—but those who underwent DMR maintained the majority of their weight loss, with significantly less rebound at six months. The procedure works by ablating the duodenal mucosa, targeting a region increasingly recognized as central to metabolic regulation. This directly addresses a growing real-world problem: while GLP-1 drugs are highly effective, 60–70% of patients discontinue them within a year due to cost, side…